{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T12:53:39Z","timestamp":1777294419575,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s11523-025-01141-9","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T17:01:22Z","timestamp":1744909282000},"page":"405-418","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Impact of Uncommon HRR Alterations as Predictors of Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1007","volume":"20","author":[{"given":"Giada","family":"Pinterpe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fortuna","family":"Migliaccio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3283-4339","authenticated-orcid":false,"given":"Chiara","family":"Ciccarese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romina Rose","family":"Pedone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachele","family":"Belletto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierluigi","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Totaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Tagliaferri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Sighinolfi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Formisano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossana","family":"Berardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernardo","family":"Rocco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giampaolo","family":"Tortora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Iacovelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"key":"1141_CR1","unstructured":"Cornford P, Tilki D, van den Bergh RCN, et al. EAU-EANM-ESTROESUR-ISUP-SIOG guidelines on prostate cancer. Arnhem, The Netherlands: European Association of Urology Guidelines Office; 2024."},{"issue":"8","key":"1141_CR2","doi-asserted-by":"publisher","first-page":"4520","DOI":"10.1007\/s12325-021-01823-6","volume":"38","author":"ND Shore","year":"2021","unstructured":"Shore ND, Lalibert\u00e9 F, Ionescu-Ittu R, et al. Real-world treatment patterns and overall survival of patients with metastatic castration-resistant prostate cancer in the US prior to PARP inhibitors. Adv Ther. 2021;38(8):4520\u201340.","journal-title":"Adv Ther"},{"issue":"18","key":"1141_CR3","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","volume":"373","author":"J Mateo","year":"2015","unstructured":"Mateo J, Carreira S, Sandhu S, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 2015;373(18):1697\u2013708.","journal-title":"N Engl J Med"},{"key":"1141_CR4","first-page":"891","volume":"383","author":"J de Bono","year":"2020","unstructured":"de Bono J, Mateo J, Fizazi KN, et al. Olaparib for metastatic castration-resistant prostate cancer. Engl J Med. 2020;383:891.","journal-title":"Engl J Med"},{"issue":"19","key":"1141_CR5","doi-asserted-by":"publisher","first-page":"4751","DOI":"10.3390\/cancers14194751","volume":"14","author":"CS McNevin","year":"2022","unstructured":"McNevin CS, Cadoo K, Baird AM, et al. PARP inhibitors in advanced prostate cancer in tumors with DNA damage signatures. Cancers (Basel). 2022;14(19):4751.","journal-title":"Cancers (Basel)."},{"issue":"24","key":"1141_CR6","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","volume":"383","author":"M Hussain","year":"2020","unstructured":"Hussain M, Mateo J, Fizazi K, et al. Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med. 2020;383(24):2345\u201357.","journal-title":"N Engl J Med"},{"issue":"5","key":"1141_CR7","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1200\/JCO.23.00339","volume":"42","author":"J Mateo","year":"2024","unstructured":"Mateo J, de Bono JS, Fizazi K, et al. Olaparib for the treatment of patients with metastatic castration-resistant prostate cancer and alterations in BRCA1 and\/or BRCA2 in the PROfound trial. J Clin Oncol. 2024;42(5):571\u201383.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1141_CR8","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJMoa2214676","volume":"388","author":"K Fizazi","year":"2023","unstructured":"Fizazi K, Piulats JM, Reaume MN, et al. Rucaparib or physician\u2019s choice in metastatic prostate cancer. N Engl J Med. 2023;388(8):719\u201332.","journal-title":"N Engl J Med"},{"issue":"1","key":"1141_CR9","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s41467-017-00393-y","volume":"8","author":"M Asim","year":"2017","unstructured":"Asim M, Tarish F, Zecchini HI, et al. Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. Nat Commun. 2017;8(1):374.","journal-title":"Nat Commun"},{"key":"1141_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/EVIDoa2200043","volume":"1","author":"NW Clarke","year":"2022","unstructured":"Clarke NW, Armstrong AJ, Thiery-Vuillemin A, et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evid. 2022;1:9.","journal-title":"NEJM Evid."},{"issue":"9","key":"1141_CR11","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.annonc.2023.06.009","volume":"34","author":"KN Chi","year":"2023","unstructured":"Chi KN, Sandhu S, Smith MR, et al. Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial. Ann Oncol. 2023;34(9):772\u201382.","journal-title":"Ann Oncol"},{"issue":"10398","key":"1141_CR12","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","volume":"402","author":"N Agarwal","year":"2023","unstructured":"Agarwal N, Azad AA, Carles J, et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet. 2023;402(10398):291\u2013303.","journal-title":"Lancet"},{"issue":"1","key":"1141_CR13","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41591-023-02704-x","volume":"30","author":"K Fizazi","year":"2024","unstructured":"Fizazi K, Azad AA, Matsubara N, et al. First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nat Med. 2024;30(1):257\u201364.","journal-title":"Nat Med"},{"key":"1141_CR14","doi-asserted-by":"publisher","first-page":"1159557","DOI":"10.3389\/fonc.2023.1159557","volume":"13","author":"AK Taylor","year":"2023","unstructured":"Taylor AK, Kosoff D, Emamekhoo H, Lang JM, Kyriakopoulos CE. PARP inhibitors in metastatic prostate cancer. Front Oncol. 2023;13:1159557.","journal-title":"Front Oncol"},{"issue":"4","key":"1141_CR15","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.eururo.2019.02.002","volume":"76","author":"CH Marshall","year":"2019","unstructured":"Marshall CH, Sokolova AO, McNatty AL, et al. Differential response to olaparib treatment among men with metastatic castration-resistant prostate cancer harboring BRCA1 or BRCA2 versus ATM mutations. Eur Urol. 2019;76(4):452\u20138.","journal-title":"Eur Urol"},{"issue":"14","key":"1141_CR16","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1200\/JCO.23.02105","volume":"42","author":"J Fallah","year":"2024","unstructured":"Fallah J, Xu J, Weinstock C, Gao X, et al. Efficacy of poly(ADP-ribose) polymerase inhibitors by individual genes in homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer: a US food and drug administration pooled analysis. J Clin Oncol. 2024;42(14):1687\u201398.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1141_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1\u201312.","journal-title":"Control Clin Trials"},{"issue":"7","key":"1141_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7): e1000097.","journal-title":"PLoS Med"},{"issue":"7414","key":"1141_CR19","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360.","journal-title":"BMJ"},{"issue":"3","key":"1141_CR20","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R Der Simonian","year":"1986","unstructured":"Der Simonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177\u201388.","journal-title":"Control Clin Trials"},{"key":"1141_CR21","unstructured":"Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. Available at: http:\/\/ims.cochrane.org\/revman\/download"},{"key":"1141_CR22","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/nature08467","volume":"461","author":"SP Jackson","year":"2009","unstructured":"Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009;461:1071\u20138.","journal-title":"Nature"},{"issue":"1","key":"1141_CR23","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1470-2045(19)30684-9","volume":"21","author":"J Mateo","year":"2020","unstructured":"Mateo J, Porta N, Bianchini D, et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21(1):162\u201374.","journal-title":"Lancet Oncol"},{"key":"1141_CR24","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1158\/2159-8290.CD-21-0007","volume":"11","author":"S Carreira","year":"2021","unstructured":"Carreira S, Porta N, Arce-Gallego S, et al. Biomarkers associating with PARP inhibitor benefit in prostate cancer in the TOPARP-B trial. Cancer Discov. 2021;11:2812\u201327.","journal-title":"Cancer Discov"},{"key":"1141_CR25","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12885-021-09082-y","volume":"22","author":"Z Lai","year":"2022","unstructured":"Lai Z, Brosnan M, Sokol ES, et al. Landscape of homologous recombination deficiencies in solid tumours: analyses of two independent genomic datasets. BMC Cancer. 2022;22:13.","journal-title":"BMC Cancer"},{"issue":"5","key":"1141_CR26","first-page":"325","volume":"30","author":"JS de Bono","year":"2019","unstructured":"de Bono JS, Fizazi K, Saad F, et al. 5118P Central, prospective detection of homologous recombination repair gene mutations (HRRm) in tumour tissue from >4000 men with metastatic castration-resistant prostate cancer (mCRPC) screened for the PROfound study. Ann Oncol. 2019;30(5):325\u201355.","journal-title":"Ann Oncol"},{"issue":"9","key":"1141_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaoncol.2021.2350","volume":"7","author":"MT Schweizer","year":"2021","unstructured":"Schweizer MT, Sivakumar S, Tukachinsky H, et al. Concordance of DNA repair gene mutations in paired primary prostate cancer samples and metastatic tissue or cell-free DNA. JAMA Oncol. 2021;7(9):1\u20135.","journal-title":"JAMA Oncol"},{"issue":"1","key":"1141_CR28","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1158\/1078-0432.CCR-22-0931","volume":"29","author":"KN Chi","year":"2023","unstructured":"Chi KN, Barnicle A, Sibilla C, et al. Detection of BRCA1, BRCA2, and ATM alterations in matched tumour tissue and circulating tumour DNA in patients with prostate cancer screened in PROfound. Clin Cancer Res. 2023;29(1):81\u201391.","journal-title":"Clin Cancer Res"},{"key":"1141_CR29","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/j.annonc.2022.07.1502","volume":"33","author":"AJ Armstrong","year":"2022","unstructured":"Armstrong AJ, Saad F, Thiery-Vuillemin A, et al. 1370P Detection of mutations in homologous recombination repair (HRR) genes in tumour tissue (TT) and circulating tumour DNA (ctDNA) from patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the phase III PROpel trial. Ann Oncol. 2022;33:1168.","journal-title":"Ann Oncol"},{"key":"1141_CR30","doi-asserted-by":"publisher","first-page":"5056","DOI":"10.1200\/JCO.2023.41.16_suppl.5056","volume":"41","author":"A Azad","year":"2023","unstructured":"Azad A, Fizazi K, Matsubara N, et al. Use of circulating tumour DNA (ctDNA) to complement tumour tissue homologous recombination repair (HRR) gene alteration testing in TALAPRO-2, a phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2023;41:5056.","journal-title":"J Clin Oncol"},{"key":"1141_CR31","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1080\/14737159.2022.2020102","volume":"22","author":"LM Van Wijk","year":"2022","unstructured":"Van Wijk LM, Nilas AB, Vrieling H, et al. RAD51 as a functional biomarker for homologous recombination deficiency in cancer: a promising addition to the HRD toolbox? Expert Rev Mol Diagn. 2022;22:185\u201399.","journal-title":"Expert Rev Mol Diagn"},{"issue":"2","key":"1141_CR32","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1128\/MCB.00465-12","volume":"33","author":"J Chun","year":"2013","unstructured":"Chun J, Buechelmaier ES, Powell SN. Rad51 paralog complexes BCDX2 and CX3 act at different stages in the BRCA1-BRCA2-dependent homologous recombination pathway. Mol Cell Biol. 2013;33(2):387\u201395.","journal-title":"Mol Cell Biol"},{"key":"1141_CR33","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1200\/JCO.2024.42.4_suppl.165","volume":"24","author":"ND Shore","year":"2024","unstructured":"Shore ND, Clarke N, Armstrong A, et al. G15P Efficacy of olaparib (O) plus abiraterone (A) versus placebo (P) plus A in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with single homologous recombination repair gene mutations (HRRm) in the PROpel trial. J Clin Oncol. 2024;24:165.","journal-title":"J Clin Oncol"},{"issue":"5_Suppl","key":"1141_CR34","doi-asserted-by":"publisher","first-page":"LBA18","DOI":"10.1200\/JCO.2025.43.5_suppl.LBA18","volume":"43","author":"N Agarwal","year":"2025","unstructured":"Agarwal N, Azad A, Carles J, et al. Final overall survival with talazoparib + enzalutamide as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial. J Clin Oncol. 2025;43(5_Suppl):LBA18.","journal-title":"J Clin Oncol"},{"issue":"5_Suppl","key":"1141_CR35","doi-asserted-by":"publisher","first-page":"LBA141","DOI":"10.1200\/JCO.2025.43.5_suppl.LBA141","volume":"43","author":"K Fizazi","year":"2025","unstructured":"Fizazi K, Azad AA, Matsubara N, et al. Final overall survival with talazoparib plus enzalutamide as initial treatment in patients with homologous recombination repair-deficient metastatic castration-resistant prostate cancer in the phase 3 TALAPRO-2 trial. J Clin Oncol. 2025;43(5_Suppl):LBA141.\u00a0","journal-title":"J Clin Oncol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01141-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-025-01141-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01141-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T11:46:58Z","timestamp":1748260018000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-025-01141-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1141"],"URL":"https:\/\/doi.org\/10.1007\/s11523-025-01141-9","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,17]]},"assertion":[{"value":"26 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"C. Ciccarese: Advisory board, invited speaker, meetings traveling: IPSEN, Merck Sharp & Dohme, Astellas, AstraZeneca, Pfizer, Janssen, and Bristol Myers Squibb, Novartis, EISAI. R. Iacovelli: Advisory board, invited speaker, meetings traveling: Pfizer, Janssen, Sanofi, IPSEN, Merck, Sharp & Dohme, Novartis, AstraZeneca, Astellas, and Bristol Myers Squibb, EISAI. G. Tortora: Consultant for BMS, MSD, Astra Zeneca, Servier, Merck Serono, Domp\u00e9. R. Berardi: Advisory board, invited speaker, meetings traveling: AstraZeneca, Boeringher, MSD, Lilly, Roche, Amgen, GSK, Eisai, BMS. L. Tagliaferri: Advisory board, invited speaker, meetings traveling: Elekta, Igea Medical, SunPharma, Sanofi, Roche, Molipharma, Nanobiotix, Novartis. G. Pinterpe, F. Migliaccio, R.R. Pedone, R. Belletto, P. Russo, A. Totaro, C. Sighinolfi, L. Formisano and B. Rocco declare that they have no conflicts of interest that might be relevant to the contents of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Giada Pinterpe, Fortuna Migliaccio, and Chiara Ciccarese: Conceptualization, data curation, formal analysis, methodology, project administration, software, investigation, writing\u2014review and editing. Romina Rose Pedone and Rachele Belletto: Resources, data curation, writing\u2014original draft. Pierluigi Russo, Angelo Totaro, Luca Tagliaferri, Chiara Sighinolfi, Luigi Formisano, Rossana Berardi and Bernardo Rocco: Methodology, investigation, resources, data curation, writing\u2014original draft, visualization. Giampaolo Tortora: Methodology, data curation, writing\u2014review and editing, visualization, supervision. Roberto Iacovelli: Conceptualization, validation, writing\u2014review and editing, visualization, supervision, project administration.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}